Tenofovir/FTC vs tenofovir as daily oral PrEP: preliminary results from Partners PrEP
1 August 2011. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
Antiretrovirals
Elvitegravir vs raltegravir: 48 week results in treatment-experienced patients
1 August 2011. Related: Conference reports, Antiretrovirals.
Dolutegravir: 48 week results from phase II study in treatment-naive patients
1 August 2011. Related: Conference reports, Antiretrovirals.
Lersivirine: 48 week results compared to efavirenz in phase 2 treatment-naive study
1 August 2011. Related: Conference reports, Antiretrovirals.
Maraviroc plus atazanavir/r without nukes versus standard of care: 48 week results
1 August 2011. Related: Conference reports, Antiretrovirals.
SPARTAC trial: treatment in primary infection for 48 weeks shows small delay in disease progression
1 August 2011. Related: Conference reports, Antiretrovirals.
Paediatric antiretroviral pipeline: darunavir and raltegravir
1 August 2011. Related: Conference reports, Antiretrovirals, Paediatric care.
FDA approve new NNRTI rilpivirine (Edurant) in the US
1 August 2011. Related: Antiretrovirals.
FDA approve new NNRTI-based fixed dose combination of rilpivirine/tenofovir/FTC (Complera) in the US
1 August 2011. Related: Antiretrovirals.
The antiretroviral pipeline
14 July 2011. Related: Pipeline report, Antiretrovirals.
Atazanavir in pregnancy: 155 cases in London clinics
1 May 2011. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy.
Quad reduces levels of oral contraceptives
1 May 2011. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Elvitegravir/cobicistat and acid reducing agents
1 May 2011. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Lopinavir/r reduces levels of rifabutin
1 May 2011. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Cobicistat has little impact on CYP2D6 and CYP2B6
1 May 2011. Related: Conference reports, Antiretrovirals.
Atazanavir levels indicate need for higher dose during pregnancy
1 May 2011. Related: Conference reports, Antiretrovirals, Pregnancy.
Etravirine lowers levels of maraviroc given at 300 or 600 mg twice daily
1 May 2011. Related: Conference reports, Antiretrovirals.
Once-daily 150-mg maraviroc explored in people taking atazanavir/ritonavir
1 May 2011. Related: Conference reports, Antiretrovirals.
Lopinavir troughs lower in children on once-daily dose with efavirenz
1 May 2011. Related: Conference reports, Antiretrovirals, Paediatric care.
Dose optimisation: 50 mg ritonavir-boosting, 3TC dosing and raltegravir once-daily
1 May 2011. Related: Conference reports, Antiretrovirals, Treatment strategies.
Rapid report: state of HCV policy, treatment, access
1 May 2011. Related: Conference reports, Antiretrovirals.
When to start ART in patients co-infected with TB: results from two trials presented at CROI
1 May 2011. Related: Conference reports, Antiretrovirals, TB coinfection.
Inflammation and intervention: how does HIV cause AIDS and how does it cause disease despite ART
1 May 2011. Related: Conference reports, Antiretrovirals.
New antiretrovirals: dolutegravir, entry inhibitor (BMS-663068) and tenofovir pro-drug (GS-7340)
1 April 2011. Related: Conference reports, Antiretrovirals.
Immune-based treatment increases HIV-resistant CD4 cells in phase 1 study
1 April 2011. Related: Conference reports, Antiretrovirals.
Antiretroviral prevention: oral PrEP, gels and treatment studies
1 April 2011. Related: Conference reports, Antiretrovirals.
Further efficacy analyses from the iPrEx study
1 April 2011. Related: Conference reports, Antiretrovirals.
Topical gels as PEP and PrEP: animal and human studies
1 April 2011. Related: Conference reports, Antiretrovirals.
Maternal risk following short course HAART
1 April 2011. Related: Conference reports, Antiretrovirals, Pregnancy.
Pre-term delivery and HAART
1 April 2011. Related: Conference reports, Antiretrovirals, Pregnancy.
HAART more effective than AZT monotherapy in the Botswana PMTCT programme
1 April 2011. Related: Conference reports, Antiretrovirals, Pregnancy.
Lopinavir/r monotherapy for PMTCT
1 April 2011. Related: Conference reports, Antiretrovirals, Pregnancy.
First results from telaprevir in HIV/HCV coinfection
1 April 2011. Related: Conference reports, Antiretrovirals, Hepatitis coinfection.
London HIV Consortium issues new guidelines for ARV prescribing (2011)
1 April 2011. Related: Antiretrovirals, Guidelines.
EMA issue restricted indication for d4T (stavudine)
1 April 2011. Related: Antiretrovirals.
Changes to starting dose of saquinavir in naive patients
1 April 2011. Related: Antiretrovirals.
FDA approve nevirapine XR
1 April 2011. Related: Antiretrovirals.
Lopinavir/r oral solution
1 April 2011. Related: Antiretrovirals.
Atazanavir use during pregnancy
1 April 2011. Related: Antiretrovirals, Pregnancy.
Nelfinavir interaction with warfarin
1 April 2011. Related: Antiretrovirals.
Lopinavir/ritonavir: women versus men
1 February 2011. Related: Conference reports, Antiretrovirals, Women's health.
Quality of life in the GRACE study
1 February 2011. Related: Conference reports, Antiretrovirals, Women's health.
Antiretroviral pharmacokinetics in women with undetectable viral load
1 February 2011. Related: Conference reports, Antiretrovirals, Women's health.
No association between bone mineral density and lipodystrophy in women receiving antiretroviral therapy
1 February 2011. Related: Conference reports, Antiretrovirals, Women's health, Weight, diabetes, metabolic complications.
The impact of antiretroviral treatment on fertility intentions in South Africa
1 February 2011. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy.
US adult treatment guidelines updated January 2011
1 February 2011. Related: Antiretrovirals, Guidelines.
FDA safety updates to antiretroviral labels
1 February 2011. Related: Antiretrovirals.
Darunavir once-daily indication in treatment experienced adults
1 February 2011. Related: Antiretrovirals.
Virological findings from the SARA trial ofboosted protease inhibitor monotherapy
1 December 2010. Related: Conference reports, Antiretrovirals, Treatment access, Virology.
Nevirapine exposure was not associated with hypersensitivity in patients from Malawi
1 December 2010. Related: Conference reports, Antiretrovirals, Side effects.
Estimating the number of people in a country or region with HIV who are undiagnosed and in need of ART
1 December 2010. Related: Conference reports, Antiretrovirals.
Efavirenz versus nevirapine based first linetreatment in a South African cohort
1 December 2010. Related: Conference reports, Antiretrovirals, Pregnancy.
GSK572: 24-week results in treatment-naive and raltegravir-experienced patients
1 December 2010. Related: Conference reports, Antiretrovirals.
Consensus guidelines recommend routine use of genotypic tropism testing: new focus on maraviroc as a switching option (2010)
1 December 2010. Related: Conference reports, Antiretrovirals, Guidelines.
Muscle weakness or pain analysed as possible raltegravir side effect
1 December 2010. Related: Conference reports, Antiretrovirals, Side effects.
Adding maraviroc does not boost CD4s inrandomised trial
1 December 2010. Related: Conference reports, Antiretrovirals.
Switch to twice-daily unboosted atazanavir outdoes switch to once-daily dose
1 December 2010. Related: Conference reports, Antiretrovirals.
Small but higher rates of AIDS and non-AIDS complications with uncontrolled HIV despite CD4s over 350
1 December 2010. Related: Conference reports, Antiretrovirals.
Once-daily raltegravir fails to demonstrate non-inferiority compared to twice-dailydosing in phase 3 treatment naive study
1 December 2010. Related: Antiretrovirals.
FDA safety updates to antiretroviral labels
1 December 2010. Related: Antiretrovirals, Side effects.
Update to US saquinavir label
1 December 2010. Related: Antiretrovirals, Side effects.
Raltegravir pharmacokinetics inpregnancy
1 October 2010. Related: Conference reports, Antiretrovirals, Pregnancy.
Low birth weight associated with HAART in pregnancy in Zambia
1 October 2010. Related: Conference reports, Antiretrovirals, Pregnancy.
Bilirubin levels in infants following in utero atazanavir exposure compared to exposure to other antiretrovirals
1 October 2010. Related: Conference reports, Antiretrovirals, Pregnancy.
Novel mutations and shifting susceptibility to darunavir and tipranavir
1 October 2010. Related: Conference reports, Antiretrovirals, Drug resistance.